Detail of the clinical trial
| Title of the trial | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer |
|---|---|
| EudraCT number | 2020-000348-77 |
| Protocol number | XL184-315 |
| Sponsor | Exelixis, Inc., 1851 Harbor Bay Parkway, CA 94502 Alameda, United States of America |
| Indications | Oncology |
| Diagnosis | prostate cancer |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Patients |
| Year of receiving the request to Institute (SÚKL) | 2020 |
| Date of approval by Institute (SÚKL) | 26.8.2020 |
| Date of approval by EC | 14.9.2020 |
| Date of initiation CT in ČR | 19.3.2021 |
| Date of ending CT in ČR | |
| Notice | |
| Sites |
Urocentrum Praha s.r.o.,,Karlovo nám. 319/3,Praha ,120 00 Fakultní nemocnice u sv. Anny v Brně,Onkologicko-chirurgické oddělení,Pekařská 53,Brno,656 91 Thomayerova nemocnice,Onkologická klinika 1. LK UK a TN,Vídeňská 800,Praha,140 59 Všeobecná fakultní nemocnice v Praze,Urologická klinika,Ke Karlovu 6,Praha 2,128 00 Nemocnice na Bulovce,Ústav radiační onkologie,Budínova 67/2,Praha 8,180 81 Fakultní nemocnice Olomouc,Onkologická klinika,I.P.Pavlova 6,Olomouc,779 00 |
cz